Abstract Library

#4667 Clinical outcomes in patients with typical (TC) and atypical bronchial carcinoids (AC): A 15-year retrospective study from an ENETS Center of Excellence

Introduction: Bronchial neuroendocrine neoplasms (NENs) can be subdivided into TCs, ACs and neuroendocrine carcinomas (NECs). Although a few studies have explored treatment approaches and oncological outcomes, most focus on surgical cohorts, small sample sizes, or mixed groups including TC, AC, and NECs. Real-life cohort data are lacking.

Conference:

Presenting Author: Clement D

Authors: Correia J, Sarker D, Dolly S, Frydman A, Srirajaskanthan R,

Keywords: bronchial carcinoid, treatment pattern, recurrence-free survival, overall survival,

#3320 TGF-β increase caspase activation and migration in typical bronchial carcinoids

Introduction: Typical bronchial carcinoids (TBC) are well-differentiated neuroendocrine neoplasms (NEN) whose management can still be very challenging due to reduced sensitivity to therapy. Previous studies have reported TGF-β’s ability to activate mTOR pathway and induce epithelial to mesenchymal transition (EMT). Moreover, preliminary results show an overexpression of TGF-β signalling and caspase activation in TBC.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Gagliardi I

Authors: Borges de Souza P, Gagliardi I, Martelli M, Zatelli M,

Keywords: bronchial carcinoid, TGF-β signalling, mTOR, EMT,

#2983 Differential TGF-β Signalling in Typical and Atypical Bronchial Carcinoids

Introduction: Typical and atypical bronchial carcinoids (TBC and ABC) are well-differentiated neuroendocrine neoplasms (NEN). Metastatic BC having low to moderate mitotic count may still be treated with somatostatin analogues and mTOR inhibitors; however, TBC and ABC have been reported to respond very differently to therapy and an effective treatment algorithm is still lacking. TGF-β is known for its ability to activate mTOR pathway and induce epithelial mesenchymal transition, affecting cell pathophysiological capabilities such as proliferation, migration and tissue invasiveness.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Borges de Souza P

Authors: Borges de Souza P, Tagliatti V, Capobianco S, Ambrosio M, Chinnici S,

Keywords: Neuroendocrine neoplasms, bronchial carcinoids, TGF-β,

#2166 A Family Bronchial Carcinoid Tumor.

Introduction: Typical and atypical bronchial carcinoids are neuroendocrine tumors of the lung. Family lung carcinoid tumors are rare and have been described as very rarely in literature.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Wassila O

Authors: Ougdi W, Bezzar-Ghomari S,

Keywords: atypical carcinoid, neuroendocrin, tumor, lung, family case.,

#1999 Study of Cell Cycle Protein Expression Pattern in Bronchial Carcinoids: A New Potential Target for Medical Therapy?

Introduction: Bronchial Carcinoids (BCs) are rare neuroendocrine neoplasms arising from respiratory epithelium. The only effective treatment option is surgery, but its efficacy is frequently limited by metastatic spread. Everolimus prolongs progression free survival but patients may develop resistance. Previous studies demonstrated that Everolimus reduces viability of NCI-H720 cells (Atypical Carcinoid) but not of NCI-H727 cells (Typical Carcinoid). Everolimus decreases Ciclyn D1 protein levels in both cell lines but NCI-H727 cells survive, indicating a derangement in cell cycle control.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Bresciani G, Riva E, Ambrosio M, Zatelli M,

Keywords: bronchial carcinoids, cell cycle, cyclins, cdks, target therapy, everolimus, dinaciclib, palbociclib,